Lamivudine Aurovitas

Lamivudine, the active ingredient in Lamivudine Aurovitas, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as an oral tablet for oral use. It treats human immunodeficiency virus (HIV) infection and chronic hepatitis B in adult patients.

GNH USA supplies Lamivudine Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions. Clients benefit from reliable logistics, batch traceability, and responsive technical support.

Lamivudine is used in antiretroviral therapy and antiviral treatment of hepatitis B, targeting viral replication. - HIV infection: reduces viral load and improves immune function in infected adults. - Chronic hepatitis B infection: suppresses HBV DNA replication and helps prevent disease progression. - Mother-to-child transmission of HIV: lowers the risk of vertical transmission when given to pregnant women. - Combination antiretroviral therapy: contributes to overall regimen efficacy in treatment‑experienced patients.

Lamivudine may cause adverse reactions ranging from mild to serious. Common Side Effects: - Nausea - Headache - Fatigue - Diarrhea Serious or Rare Side Effects: - Lactic acidosis - Severe hepatotoxicity - Pancreatitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When prescribing lamivudine, clinicians should observe several precautionary measures to ensure patient safety. - Monitor liver function: assess baseline enzymes and follow up regularly. - Assess renal function: adjust dose in patients with impaired clearance. - Screen for hypersensitivity: discontinue if rash or systemic allergic signs appear. - Avoid use in patients with known mitochondrial toxicity: risk of lactic acidosis. - Use caution during pregnancy: weigh benefits against potential risks. - Store at room temperature: keep in original packaging, protect from moisture and heat.

Lamivudine can interact with other medicines, influencing efficacy or toxicity. Major Interactions (Avoid): - Didanosine: combined use increases risk of pancreatitis. - Stavudine: concurrent therapy may exacerbate mitochondrial toxicity. - Ribavirin: may enhance hematologic toxicity. Moderate Interactions (Monitor Closely): - Efavirenz: may affect lamivudine plasma levels, requiring monitoring. - Nevirapine: potential for increased liver enzyme elevations. - Warfarin: monitor INR as lamivudine may alter anticoagulant effect. - Oral contraceptives: assess hormonal efficacy, though interaction is limited.